{"filing":{"accession_number":"0001193125-26-294613","cik":"0001782223","ticker":"PYXS","company_name":"Pyxis Oncology, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"pyxs-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526294613/pyxs-20260630.htm"},"events":[{"id":15869,"run_id":14155,"accession_number":"0001193125-26-294613","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Pyxis Oncology entered into a securities purchase agreement on June 30, 2026, to issue 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number of shares at $3.289 per share, generating approximately $50 million in gross upfront proceeds with potential additional $64 million if warrants are exercised. This private placement significantly extends the company's cash runway into Q2 2027 and funds advancement of its lead clinical program.","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":[{"id":13778,"accession_number":"0001193125-26-294613","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Pyxis Oncology entered into a securities purchase agreement on June 30, 2026, to issue 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number of shares at $3.289 per share, generating approximately $50 million in gross upfront proceeds (with potential additional $64 million if warrants are exercised). This is a classic private placement of unregistered equity securities by a clinical-stage biopharmaceutical company raising capital, fitting the dilutive_issuance category. The transaction is material as it significantly extends the company's cash runway into Q2 2027 and funds advancement of its lead clinical program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:22:06.715757+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13779,"accession_number":"0001193125-26-294613","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Pyxis Oncology disclosed an unregistered private placement of approximately $50 million in gross proceeds upfront, with an additional ~$64 million potential from warrant exercises. The company is selling 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number at $3.289 per share, relying on Section 4(a)(2) exemption from Securities Act registration. This is a classic dilutive equity issuance to raise capital, material to investors assessing ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:22:06.715757+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13780,"accession_number":"0001193125-26-294613","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Pyxis Oncology announced a private placement of approximately $50 million in gross proceeds (with potential for up to $114 million if warrants are exercised), involving the sale of 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number of shares. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, materially affecting existing shareholders through equity dilution and extending the company's cash runway into Q2 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:22:06.715757+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13778,"accession_number":"0001193125-26-294613","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Pyxis Oncology entered into a securities purchase agreement on June 30, 2026, to issue 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number of shares at $3.289 per share, generating approximately $50 million in gross upfront proceeds (with potential additional $64 million if warrants are exercised). This is a classic private placement of unregistered equity securities by a clinical-stage biopharmaceutical company raising capital, fitting the dilutive_issuance category. The transaction is material as it significantly extends the company's cash runway into Q2 2027 and funds advancement of its lead clinical program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:22:06.715757+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-07-02"},{"id":13779,"accession_number":"0001193125-26-294613","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Pyxis Oncology disclosed an unregistered private placement of approximately $50 million in gross proceeds upfront, with an additional ~$64 million potential from warrant exercises. The company is selling 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number at $3.289 per share, relying on Section 4(a)(2) exemption from Securities Act registration. This is a classic dilutive equity issuance to raise capital, material to investors assessing ownership dilution and the company's financing strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:22:06.715757+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-07-02"},{"id":13780,"accession_number":"0001193125-26-294613","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Pyxis Oncology announced a private placement of approximately $50 million in gross proceeds (with potential for up to $114 million if warrants are exercised), involving the sale of 19,600,153 shares of common stock at $2.551 per share plus warrants to purchase an equal number of shares. This is a classic dilutive equity issuance by a clinical-stage biopharmaceutical company raising capital, materially affecting existing shareholders through equity dilution and extending the company's cash runway into Q2 2027.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T20:22:06.715757+00:00","company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","filing_date":"2026-07-02"}]}